Lung Cancer

Aspirin is biologically relevant in lung cancer for three main reasons.

The first is long-term prevention in high-risk populations.

The second is anti-metastatic platelet biology, especially through TXA2 signalling and circulating tumour-cell survival.

The third is possible chemotherapy sensitisation, especially in cisplatin-resistant non-small cell lung cancer.

There is still no Phase 3 adjuvant aspirin trial in lung cancer.

That means the evidence base is mostly observational plus mechanistic.

Even so, the signal is consistent enough to take seriously. Read the review

Overview

Lung cancer remains the leading cause of cancer death worldwide.

Non-small cell lung cancer makes up about 85% of cases.

This cancer also has some of the most active platelet–tumour biology of any solid tumour.

That matters because circulating lung-cancer cells often rely on platelet cloaking to survive in the bloodstream and seed distant sites.

This makes aspirin's TXA2 and anti-platelet effects especially relevant here.

At the same time, non-small cell lung cancer often carries pathway changes in PIK3CA, KRAS, and EGFR that overlap with aspirin-sensitive biology. Read the study

Key human data

Long-term prevention

One of the strongest recent population findings comes from the 2025 Danish registry cohort.

Among 538,147 low-dose aspirin users followed for more than 10 years, lung-cancer risk was reduced by 44% compared with non-users, with a subdistribution hazard ratio of 0.56. Read the PubMed record

That reduction was not seen with shorter use.

The signal only emerged with more than 10 years of consistent low-dose aspirin exposure.

That suggests any lung-cancer prevention effect is a long-term biological shift, not a short-course intervention.

Other long-term population datasets also support lower lung-cancer incidence in regular aspirin users, often in the range of about 20% to 40%, with stronger effects in current or former smokers. Read the review

That fits the epidemiology.

Smokers and former smokers sit in the highest-risk group, so that is where a long-term preventive signal would matter most.

Post-diagnosis and survival

Human post-diagnosis data is much thinner than the prevention literature.

Still, one retrospective cohort in inoperable non-small cell lung cancer reported significantly improved overall survival in aspirin users compared with non-users. Read the report

That does not establish causation.

But it is one of the more relevant human datasets because it looks specifically at lung cancer after diagnosis rather than prevention before diagnosis.

Broader observational meta-analyses across cancer types also suggest better survival and less metastatic spread with aspirin use, and lung cancer is usually part of that pattern. Read the overview

The ASPREE caution

The ASPREE and ASPREE-XT studies need to be interpreted carefully.

In generally healthy older adults with a median age of 74, aspirin did not reduce overall cancer incidence and was associated with higher cancer mortality at about five years. Read the summary

This is not usually interpreted to mean aspirin causes cancer.

The more plausible reading is that age, population selection, and timing matter a great deal.

Late-life aspirin exposure in an unselected older population is not the same question as long-term low-dose use in a high-risk population, or aspirin use in a biologically selected cancer setting.

Mechanistic relevance

TXA2 and platelet-supported metastasis

This is probably the strongest lung-cancer aspirin mechanism.

TXA2 synthase is expressed in lung tumour-associated endothelial cells, and TXA2 supports angiogenesis through VEGF, EGFR, Src, and ERK signalling. Read the mechanism study

The 2025 Nature study made this more clinically interesting.

It showed that platelet-derived TXA2 suppresses CD8-positive T-cell killing through an ARHGEF1 → RhoA pathway, and lung metastasis was one of the main experimental systems used to validate that effect. Read the Nature paper

In that work:

• platelet-derived TXA2 blocked effective T-cell attack on circulating tumour cells

• aspirin restored T-cell activity in tumour-bearing lungs

• giving back a TXA2 analog reversed aspirin's anti-metastatic effect

That is strong mechanistic evidence that the COX-1 → TXA2 → ARHGEF1 axis matters in lung metastatic biology. Read a clinical summary

For the broader mechanism page, see Aspirin and Thromboxane A2 (TXA2).

Cisplatin sensitisation

Lung cancer also has an important second aspirin mechanism.

It may help reverse cisplatin resistance in resistant non-small cell lung cancer stem-cell models.

In a 2019 study, cisplatin-resistant stem-like lung-cancer cells showed hyperactivation of the mTOR, Akt, and PI3K axis. Aspirin pre-treatment suppressed mTOR transcription, reduced Akt activation, reactivated GSK3β, and restored cisplatin sensitivity. Read the study

That matters because it appears to be at least partly COX-independent.

In other words, aspirin may have lung-cancer relevance even when classic COX-2 signalling is not the dominant driver.

This is still preclinical.

But it is one of the more credible combination-use signals in this cancer type.

COX-2 and inflammatory pressure

The older inflammation story still matters.

COX-2 is overexpressed in many non-small cell lung cancers and often tracks with worse prognosis. Aspirin can reduce PGE2-driven proliferation, immune escape, and angiogenic signalling in lung-cancer models. Read the review

This mechanism is less specific than the TXA2 story.

But it supports the broader biological rationale.

Aspirin-exacerbated respiratory disease

This is the most important safety issue that is specific to lung cancer.

Around 10% to 20% of adults with asthma, and a higher proportion of people with nasal polyps, may have aspirin-exacerbated respiratory disease. Read the review

This is a hypersensitivity reaction to aspirin and other non-steroidal anti-inflammatory drugs.

It can cause:

• bronchospasm

• nasal and sinus symptoms

• respiratory compromise in severe cases

This matters even more in lung-cancer patients because many already have:

• chronic obstructive pulmonary disease

• asthma

• reduced lung reserve

• prior thoracic radiation or lung surgery

Clinical positioning

Practical interpretation

The lung-cancer aspirin literature is more convincing on biology than on definitive clinical proof.

The best-supported themes are:

• very long-term prevention in higher-risk populations

• platelet and TXA2 suppression during metastasis

• possible re-sensitisation of cisplatin-resistant non-small cell lung cancer

For many readers, the most useful questions for the care team are:

1. Do I have any history of aspirin sensitivity, asthma, or nasal polyps?

2. What is my lung-cancer subtype, and are PIK3CA, EGFR, or related pathways part of the biology?

3. Am I receiving cisplatin-based chemotherapy, and is resistance suspected?

4. Do my platelets, clotting history, or metastatic pattern suggest active platelet-supported disease biology?

The current evidence does not put lung cancer in the same category as biomarker-selected colorectal cancer.

But the TXA2 and metastasis story is among the strongest aspirin mechanisms in any non-gastrointestinal tumour type.

References

• Danish registry cohort, 2025 — more than 10 years of low-dose aspirin use and lower lung-cancer risk. Read the PubMed record

• Yang et al., Nature 2025 — TXA2, ARHGEF1, and anti-metastatic immune restoration in lung metastasis models. Read the Nature paper

• Clinical summary of the anti-metastatic TXA2 mechanism. Read the summary

• 2019 Scientific Reports paper — aspirin re-sensitises cisplatin-resistant non-small cell lung cancer stem cells through mTOR and Akt effects. Read the study

• Retrospective cohort in inoperable non-small cell lung cancer. Read the report

• Broader review of aspirin mechanisms and clinical outcomes in cancer. Read the review

• ASPREE and older-adult caution summary. Read the summary

• Review of aspirin-exacerbated respiratory disease and respiratory safety context. Read the review

• Systematic review of aspirin's anti-metastatic role. Read the review

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form